CASTLE BIOSCIENCES INC (CSTL) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CSTL currently has 29.9M outstanding shares. with limited dilution risk as only 1.01M additional shares (3.4%) are authorized for issuance. The company has minimally diluted shareholders by 8.14% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 06, 2026 |
10-Q filing | 29.9M shares outstanding |
30M | 1M |
| Aug 04, 2025 |
10-Q filing | 28.9M shares outstanding |
29M | 2M |
| May 05, 2025 |
10-Q filing | 28.6M shares outstanding |
29M | 2.3M |
| Feb 27, 2025 |
10-K filing | 27.8M shares outstanding |
28M | 3.1M |
| Nov 04, 2024 |
10-Q filing | 27.8M shares outstanding |
28M | 3.1M |
| Aug 05, 2024 |
10-Q filing | 27.6M shares outstanding |
28M | 3.3M |
| May 02, 2024 |
10-Q filing | 27.5M shares outstanding |
27M | 3.4M |
| Feb 28, 2024 |
S-3 filing: The company may offer and sell up to $300,000,000 of any combination of common stock, preferred stock, and debt securities from time to time. |
27M | 4.1M |
| Feb 28, 2024 |
10-K filing | 26.8M shares outstanding |
27M | 4.1M |
| Nov 02, 2023 |
10-Q filing | 26.8M shares outstanding |
27M | 0 |
| Aug 02, 2023 |
10-Q filing | 26.7M shares outstanding |
27M | 0 |
| May 03, 2023 |
10-Q filing | 26.6M shares outstanding |
27M | 0 |
| Feb 28, 2023 |
10-K filing | 26.1M shares outstanding |
26M | 0 |
| Nov 02, 2022 |
10-Q filing | 26.3M shares outstanding |
26M | 0 |
| Aug 08, 2022 |
10-Q filing | 26.1M shares outstanding |
26M | 0 |
| May 09, 2022 |
10-Q filing | 25.4M shares outstanding |
25M | 0 |
| May 02, 2022 |
8-K filing: Castle Biosciences, Inc. completed its acquisition of AltheaDx, Inc. and issued 763,887 shares of its common stock as part of the initial consideration. ($32.5M proceeds) |
25M | 0 |
| Apr 04, 2022 |
8-K filing: Castle Biosciences, Inc. entered into an agreement to acquire AltheaDx, Inc., with consideration including $32.5 million in cash and $32.5 million in shares of Castle Biosciences' common stock, plus potential milestone payments of up to $75.0 million, paid 50% in cash and 50% in stock, subject to a cap of 4.99% of outstanding shares. |
25M | 0 |
| Feb 28, 2022 |
10-K filing | 25.1M shares outstanding |
25M | 0 |
| Nov 08, 2021 |
10-Q filing | 25.3M shares outstanding |
25M | 0 |
| Aug 09, 2021 |
10-Q filing | 25.1M shares outstanding |
25M | 0 |
| May 10, 2021 |
10-Q filing | 24.9M shares outstanding |
25M | 0 |
| Mar 11, 2021 |
10-K filing | 25.0M shares outstanding |
25M | 0 |
| Dec 16, 2020 |
8-K filing: Castle Biosciences, Inc. announced a public offering of 4,000,000 shares of its common stock at a price of $58.00 per share, with the underwriters having a 30-day option to purchase up to 600,000 additional shares. ($217.3M proceeds) |
20M | 0 |
| Nov 09, 2020 |
10-Q filing | 19.9M shares outstanding |
20M | 0 |
| Aug 10, 2020 |
10-Q filing | 19.7M shares outstanding |
20M | 0 |
| Jun 30, 2020 |
8-K filing: Castle Biosciences, Inc. completed a public offering of 2,000,000 shares of common stock at a price of $37.00 per share, resulting in gross proceeds of $74.0 million before deducting underwriting discounts and commissions and other offering expenses. ($74.0M proceeds) |
17M | 1.7M |
| Jun 22, 2020 |
S-1 filing: This S-1 filing relates to an offering of common stock by Castle Biosciences, Inc. The company intends to use the net proceeds from this offering to support research and development activities, expand its commercial organization, and for working capital and other general corporate purposes. |
17M | 1.7M |
| May 11, 2020 |
10-Q filing | 17.2M shares outstanding |
17M | 0 |
| Mar 10, 2020 |
10-K filing | 17.2M shares outstanding |
17M | 0 |